Literature DB >> 8738265

Daily rhythm of serum melatonin in patients with dementia of the degenerate type.

K Uchida1, N Okamoto, K Ohara, Y Morita.   

Abstract

The daily rhythm in serum melatonin levels was measured in patients with dementia of the degenerate type (Alzheimer's disease, Pick's disease and senile dementia of the Alzheimer type) by radioimmunoassay. Thirteen patients (age: 69.0 +/- 8.0 years, mean +/- S.D.) were studied. All patients were hospitalized at the time of the study and had a history of sleep-wake disturbances, nocturnal wandering and/or delirium. We also studied 13 age-matched healthy control subjects (control group 1), ten young adults (control group 2), and nine hospitalized patients without dementia (control group 3). Two subjects in the control groups showed no measurable changes in melatonin level throughout the day, while the other 30 control subjects exhibited a clear daily rhythm with the peak concentration occurring during the night. On the other hand, four out of the 13 patients with dementia did not show any melatonin rhythm. Two of the demented patients who did not exhibit melatonin rhythm displayed clinical symptoms of rhythm disorders. One out of the nine patients with melatonin rhythm presented with clinical symptoms, such as delirium and sleep-wake disturbance. Our results suggest that the probability of absent melatonin rhythm is higher in demented patients compared with subjects without dementia. However, a lack of melatonin rhythm is not always associated with symptomatic rhythm disorders. Since the melatonin rhythm reflects that of the suprachiasmatic nucleus, it follows that the SCN function of the patients having a history of rhythm disorders was not always severely damaged.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738265     DOI: 10.1016/0006-8993(96)00086-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  35 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 3.  Aging, circadian rhythms and depressive disorders: a review.

Authors:  Inês Campos Costa; Hugo Nogueira Carvalho; Lia Fernandes
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

4.  Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway.

Authors:  Xiong Wang; Zhi-Hao Wang; Yuan-Yuan Wu; Hui Tang; Lu Tan; Xiang Wang; Xin-Ya Gao; Yan-Si Xiong; Dan Liu; Jian-Zhi Wang; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2012-10-07       Impact factor: 5.590

Review 5.  Treatment of Sleep Disorders in Dementia.

Authors:  Sharon Ooms; Yo-El Ju
Journal:  Curr Treat Options Neurol       Date:  2016-09       Impact factor: 3.598

Review 6.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

Review 7.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 8.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 9.  Rhythms of life: circadian disruption and brain disorders across the lifespan.

Authors:  Ryan W Logan; Colleen A McClung
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

10.  Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.

Authors:  Erik S Musiek; Meghana Bhimasani; Margaret A Zangrilli; John C Morris; David M Holtzman; Yo-El S Ju
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.